C57BL/6JCya-Ptk6em1flox/Cya
Common Name:
Ptk6-flox
Product ID:
S-CKO-05057
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Ptk6-flox
Strain ID
CKOCMP-20459-Ptk6-B6J-VA
Gene Name
Product ID
S-CKO-05057
Gene Alias
BRK; Sik; Tksk; tks
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
2
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Ptk6em1flox/Cya mice (Catalog S-CKO-05057) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000016511
NCBI RefSeq
NM_009184
Target Region
Exon 2~5
Size of Effective Region
~2.9 kb
Detailed Document
Overview of Gene Research
PTK6, also known as Breast tumor kinase (Brk), is an intracellular tyrosine kinase distantly related to SRC family kinases. It functions in cell-type and context-dependent processes governing normal differentiation. In tumors, overexpressed PTK6 acts as a mediator of cancer cell phenotypes such as increased proliferation, survival, and migration. It phosphorylates nuclear and cytoplasmic substrates including regulatory RNA-binding proteins, adaptor molecules, and STAT molecules, influencing key signaling pathways [4].
PTK6 is overexpressed in multiple cancers. In clear cell renal carcinoma (KIRC), its overexpression is linked to worse outcomes, higher immune infiltration, and correlates with neo-antigens and DNA ploidy changes, suggesting it as a biomarker for prognosis and treatment [1]. In triple-negative breast cancer, especially in the lymph node metastasis positive group, PTK6 expression is higher and associated with poor prognosis [2]. In uveal melanoma, PTK6 promotes tumorigenesis by inhibiting autophagy through binding to SOCS3 and regulating mTOR phosphorylation [3]. In prostate cancer, elevated PTK6 expression, its translocation from the nucleus to the cytoplasm and activation at the plasma membrane promote cancer progression by phosphorylating substrates like AKT, p130CAS, and FAK [5]. Vemurafenib can inhibit active PTK6 in PTEN-null prostate tumor cells [6]. In Her2(+) breast cancer, PTK6 inhibition promotes apoptosis of Lapatinib-resistant cells by inducing Bim [7]. In hepatocellular carcinoma, PTK6 promotes cell proliferation and invasion [8]. In colorectal cancer, PTK6 activates autophagy and inhibits apoptosis by driving HNRNPH1 phase separation [9].
In conclusion, PTK6 plays a significant role in promoting cancer cell growth, metastasis, and survival across various cancer types. Its overexpression and activation are associated with poor prognosis in multiple cancers. The study of PTK6 in these disease models helps in understanding cancer-related biological processes, providing potential targets for cancer therapies.
References：
1. Lin, Lizhen, Gong, Siming, Deng, Chao, Zhang, Guanxiong, Wu, Jing. 2024. PTK6: An emerging biomarker for prognosis and immunotherapeutic response in clear cell renal carcinoma (KIRC). In Heliyon, 10, e29001. doi:10.1016/j.heliyon.2024.e29001. https://pubmed.ncbi.nlm.nih.gov/38596018/
2. Chen, Yuexia, Qu, Wei, Tu, Jianhong, Yang, Liu, Gui, Xingxing. 2023. Prognostic impact of PTK6 expression in triple negative breast cancer. In BMC women's health, 23, 575. doi:10.1186/s12905-023-02736-y. https://pubmed.ncbi.nlm.nih.gov/37932734/
3. Liu, Bo, Yao, Xueting, Zhang, Chaoyang, Hu, Danning, Wu, Wencan. 2023. PTK6 inhibits autophagy to promote uveal melanoma tumorigenesis by binding to SOCS3 and regulating mTOR phosphorylation. In Cell death & disease, 14, 55. doi:10.1038/s41419-023-05590-w. https://pubmed.ncbi.nlm.nih.gov/36690663/
4. Ostrander, Julie H, Daniel, Andrea R, Lange, Carol A. 2010. Brk/PTK6 signaling in normal and cancer cell models. In Current opinion in pharmacology, 10, 662-9. doi:10.1016/j.coph.2010.08.007. https://pubmed.ncbi.nlm.nih.gov/20832360/
5. Zheng, Yu, Tyner, Angela L. 2013. Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer. In European journal of clinical investigation, 43, 397-404. doi:10.1111/eci.12050. https://pubmed.ncbi.nlm.nih.gov/23398121/
6. Wozniak, Darren J, Hitchinson, Ben, Gilic, Milica B, Gaponenko, Vadim, Tyner, Angela L. 2019. Vemurafenib Inhibits Active PTK6 in PTEN-null Prostate Tumor Cells. In Molecular cancer therapeutics, 18, 937-946. doi:10.1158/1535-7163.MCT-18-0862. https://pubmed.ncbi.nlm.nih.gov/30926642/
7. Park, Sun Hee, Ito, Koichi, Olcott, William, Halstead-Nussloch, Gwyneth, Irie, Hanna Y. 2015. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim. In Breast cancer research : BCR, 17, 86. doi:10.1186/s13058-015-0594-z. https://pubmed.ncbi.nlm.nih.gov/26084280/
8. Chen, Xiaohong, Song, Bo, Lin, Yuanlong, Zhang, Lin, Wang, Fuxiang. 2016. PTK6 promotes hepatocellular carcinoma cell proliferation and invasion. In American journal of translational research, 8, 4354-4361. doi:. https://pubmed.ncbi.nlm.nih.gov/27830019/
9. Chen, Bingyuan, Liu, Bowen, Chen, Junnan, Jiang, Tao, Song, Jun. 2025. PTK6 drives HNRNPH1 phase separation to activate autophagy and suppress apoptosis in colorectal cancer. In Autophagy, , 1-20. doi:10.1080/15548627.2025.2481001. https://pubmed.ncbi.nlm.nih.gov/40103198/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen